Greenwich LifeSciences (GLSI) Competitors

Greenwich LifeSciences logo
$13.76 -1.18 (-7.90%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$13.68 -0.08 (-0.58%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GLSI vs. PHAR, AKTS, MGTX, ORIC, and GLUE

Should you buy Greenwich LifeSciences stock or one of its competitors? Greenwich LifeSciences's main competitors and comparable companies include Pharming Group (PHAR), Aktis Oncology (AKTS), MeiraGTx (MGTX), Oric Pharmaceuticals (ORIC), and Monte Rosa Therapeutics (GLUE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Greenwich LifeSciences compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Pharming Group had 3 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 6 mentions for Pharming Group and 3 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.91 beat Pharming Group's score of 0.65 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharming Group
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Greenwich LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pharming Group has a net margin of 6.23% compared to Greenwich LifeSciences' net margin of 0.00%. Pharming Group's return on equity of 8.70% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Pharming Group6.23% 8.70% 4.93%
Greenwich LifeSciences N/A -793.81%-295.32%

Pharming Group has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharming Group$376.13M2.37$2.85M$0.3239.34
Greenwich LifeSciencesN/AN/A-$19.36M-$1.54N/A

Pharming Group has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Pharming Group currently has a consensus price target of $39.67, indicating a potential upside of 215.06%. Greenwich LifeSciences has a consensus price target of $69.00, indicating a potential upside of 401.45%. Given Greenwich LifeSciences' higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than Pharming Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Greenwich LifeSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 51.3% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Pharming Group beats Greenwich LifeSciences on 10 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 51.3% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aktis Oncology currently has a consensus target price of $35.63, suggesting a potential upside of 120.45%. Greenwich LifeSciences has a consensus target price of $69.00, suggesting a potential upside of 401.45%. Given Greenwich LifeSciences' higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than Aktis Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aktis Oncology
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Greenwich LifeSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Greenwich LifeSciences has lower revenue, but higher earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aktis Oncology$6.50M133.63-$63.73M-$0.82N/A
Greenwich LifeSciencesN/AN/A-$19.36M-$1.54N/A

In the previous week, Aktis Oncology had 7 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 10 mentions for Aktis Oncology and 3 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.91 beat Aktis Oncology's score of 0.11 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aktis Oncology
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Greenwich LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aktis Oncology's return on equity of 0.00% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aktis OncologyN/A N/A N/A
Greenwich LifeSciences N/A -793.81%-295.32%

Summary

Aktis Oncology beats Greenwich LifeSciences on 9 of the 13 factors compared between the two stocks.

How does Greenwich LifeSciences compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

MeiraGTx has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Greenwich LifeSciences has lower revenue, but higher earnings than MeiraGTx. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$81.39M10.31-$114.20M$0.8010.93
Greenwich LifeSciencesN/AN/A-$19.36M-$1.54N/A

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 51.3% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, MeiraGTx had 8 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 11 mentions for MeiraGTx and 3 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.91 beat MeiraGTx's score of -0.32 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MeiraGTx
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Greenwich LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MeiraGTx has a net margin of 19.46% compared to Greenwich LifeSciences' net margin of 0.00%. MeiraGTx's return on equity of 154.51% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
MeiraGTx19.46% 154.51% 26.50%
Greenwich LifeSciences N/A -793.81%-295.32%

MeiraGTx currently has a consensus price target of $24.00, suggesting a potential upside of 174.60%. Greenwich LifeSciences has a consensus price target of $69.00, suggesting a potential upside of 401.45%. Given Greenwich LifeSciences' higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than MeiraGTx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MeiraGTx
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.63
Greenwich LifeSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

MeiraGTx beats Greenwich LifeSciences on 10 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 51.3% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 3 mentions for Greenwich LifeSciences. Oric Pharmaceuticals' average media sentiment score of 1.33 beat Greenwich LifeSciences' score of 0.91 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oric Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Greenwich LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oric Pharmaceuticals presently has a consensus price target of $21.25, indicating a potential upside of 182.58%. Greenwich LifeSciences has a consensus price target of $69.00, indicating a potential upside of 401.45%. Given Greenwich LifeSciences' higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than Oric Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oric Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81
Greenwich LifeSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Oric Pharmaceuticals' return on equity of -35.35% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Oric PharmaceuticalsN/A -35.35% -33.39%
Greenwich LifeSciences N/A -793.81%-295.32%

Oric Pharmaceuticals has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oric PharmaceuticalsN/AN/A-$129.47M-$1.35N/A
Greenwich LifeSciencesN/AN/A-$19.36M-$1.54N/A

Summary

Oric Pharmaceuticals beats Greenwich LifeSciences on 8 of the 12 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Monte Rosa Therapeutics had 7 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 10 mentions for Monte Rosa Therapeutics and 3 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.91 beat Monte Rosa Therapeutics' score of 0.05 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monte Rosa Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Greenwich LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 51.3% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Greenwich LifeSciences has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -186.24%. Monte Rosa Therapeutics' return on equity of -30.14% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics-186.24% -30.14% -20.35%
Greenwich LifeSciences N/A -793.81%-295.32%

Monte Rosa Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Monte Rosa Therapeutics presently has a consensus price target of $26.44, indicating a potential upside of 188.69%. Greenwich LifeSciences has a consensus price target of $69.00, indicating a potential upside of 401.45%. Given Greenwich LifeSciences' higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than Monte Rosa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75
Greenwich LifeSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Greenwich LifeSciences has lower revenue, but higher earnings than Monte Rosa Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$123.67M6.33-$38.63M-$1.40N/A
Greenwich LifeSciencesN/AN/A-$19.36M-$1.54N/A

Summary

Monte Rosa Therapeutics beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLSI vs. The Competition

MetricGreenwich LifeSciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$224.28M$4.15B$7.84B$12.17B
Dividend YieldN/A3.62%2.46%4.42%
P/E Ratio-8.9428.4134.0828.13
Price / SalesN/A16.028.535.69
Price / CashN/A26.3721.9322.50
Price / Book458.674.074.403.70
Net Income-$19.36M-$22.86M$3.52B$392.17M
7 Day Performance-14.37%-6.05%-4.42%-3.37%
1 Month Performance-5.43%-4.82%-3.47%-5.83%
1 Year Performance67.19%-3.06%0.15%-6.24%

Greenwich LifeSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLSI
Greenwich LifeSciences
1.531 of 5 stars
$13.76
-7.9%
$69.00
+401.5%
+65.4%$224.28MN/AN/A13
PHAR
Pharming Group
3.8567 of 5 stars
$13.14
-0.2%
$39.67
+202.0%
-25.1%$929.70M$376.13M41.05407
AKTS
Aktis Oncology
1.6122 of 5 stars
$17.20
+5.0%
$35.63
+107.2%
N/A$927.73M$6.50MN/A79
MGTX
MeiraGTx
2.557 of 5 stars
$9.61
+1.2%
$24.00
+149.9%
+6.7%$922.27M$81.39M13.53393
ORIC
Oric Pharmaceuticals
3.4798 of 5 stars
$8.84
-4.2%
$21.25
+140.4%
-38.6%$916.27MN/AN/A111

Related Companies and Tools


This page (NASDAQ:GLSI) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners